Warning sign for potential anti-cancer approach

One treatment being investigated as an adjuvant for anticancer immunotherapies is the use of molecules that trigger the proteins TLR7 and TLR8. However, new research, to be published in the Journal of Clinical Investigation, suggests that such approaches should be developed with caution because stimulation of human lung cancer cells with TLR7 or TLR8 agonists increased tumor cell survival and resistance to chemotherapeutics.